Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government
Portfolio Pulse from Vandana Singh
Johnson & Johnson (JNJ) has joined other pharmaceutical companies in legal action against the U.S. government over a program that allows Medicare to negotiate lower drug prices. The pharmaceutical sector argues that the program will limit profits and hinder the development of new treatments. The Biden administration expects the program to save $25 billion annually by 2031. Other companies involved in legal action against the program include Bristol Myers Squibb (BMY) and Merck & Co (MRK).
July 19, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol Myers Squibb is involved in legal action against the U.S. government over a program that could potentially lower its drug prices, which may impact its profits.
The legal action against the U.S. government's drug pricing negotiation program could potentially lead to lower drug prices for Bristol Myers Squibb, which could impact the company's profits.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Johnson & Johnson is taking legal action against the U.S. government over a program that could potentially lower its drug prices, which may impact its profits.
The legal action against the U.S. government's drug pricing negotiation program could potentially lead to lower drug prices for Johnson & Johnson, which could impact the company's profits.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck & Co is involved in legal action against the U.S. government over a program that could potentially lower its drug prices, which may impact its profits.
The legal action against the U.S. government's drug pricing negotiation program could potentially lead to lower drug prices for Merck & Co, which could impact the company's profits.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80